Innate immunity in Huntington´s disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985904%3A_____%2F20%3A00536500" target="_blank" >RIV/67985904:_____/20:00536500 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Innate immunity in Huntington´s disease

Popis výsledku v původním jazyce

Huntington's disease (HD) is an inherited progressive neurodegenerative disorder with impairment of motor and cognitive functions. Any preventive or disease-modifying therapies are not available so far. Symptomatic treatment can only affect symptoms and it is not satisfying. Several approaches using RNAi to lower the expression of mutant huntingtin (mHTT) have been developed to date. In order to monitor the success of therapy efficacy in the pre-manifest stages of HD it is important to identify robust biomarkers of the onset and disease progression. The primary pathology of HD results inter alia from massive degeneration of neurons in the basal ganglia and thalamus. However, the expression of mutant huntingtin was detected in all examined tissues. Studies on HD demonstrated altered immune response in HD gene carriers indicating that cytokines may have a significant role in disease development. Therefore, cerebrospinal fluid (CSF) and blood serum may provide insight into pathology of HD, new prospective biomarkers and potential therapeutic targets. Additionally, microglia and monocytes could also serve as possible cellular source of candidate biomarkers to monitor HD progression.

Název v anglickém jazyce

Innate immunity in Huntington´s disease

Popis výsledku anglicky

Huntington's disease (HD) is an inherited progressive neurodegenerative disorder with impairment of motor and cognitive functions. Any preventive or disease-modifying therapies are not available so far. Symptomatic treatment can only affect symptoms and it is not satisfying. Several approaches using RNAi to lower the expression of mutant huntingtin (mHTT) have been developed to date. In order to monitor the success of therapy efficacy in the pre-manifest stages of HD it is important to identify robust biomarkers of the onset and disease progression. The primary pathology of HD results inter alia from massive degeneration of neurons in the basal ganglia and thalamus. However, the expression of mutant huntingtin was detected in all examined tissues. Studies on HD demonstrated altered immune response in HD gene carriers indicating that cytokines may have a significant role in disease development. Therefore, cerebrospinal fluid (CSF) and blood serum may provide insight into pathology of HD, new prospective biomarkers and potential therapeutic targets. Additionally, microglia and monocytes could also serve as possible cellular source of candidate biomarkers to monitor HD progression.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

<a href="/cs/project/LO1609" target="_blank" >LO1609: Modely závažných lidských onemocnění: Traumatické poškození míchy, Huntingtonova choroba, melanom a neplodnost</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Translational Research in Serious Human Diseases

ISBN

978-80-200-3158-7

Počet stran výsledku

8

Strana od-do

49-56

Počet stran knihy

271

Název nakladatele

Academia

Místo vydání

Praha

Kód UT WoS kapitoly

—